Sulforaphane Detoxification: What Human Pollution & Smoker Trials Show

Sulforaphane has human “detoxification” evidence—but the claim is much narrower than supplement marketing usually implies. Randomized trials show that broccoli-sprout-derived sulforaphane systems can increase urinary excretion of selected metabolites of benzene, acrolein and other volatile pollutants. They do not prove a whole-body cleanse, liver repair, reversal of smoking damage or prevention of pollution-related disease.

The useful scientific term here is xenobiotic metabolism: how the body processes and eliminates foreign chemicals. Sulforaphane can influence stress-response and Phase II enzyme systems involved in that process, but the strongest human evidence measures specific urinary biomarkers—not a generic “toxin load.”

What does “detox” mean in the human sulforaphane trials?

Several trials measured urinary mercapturic acids, downstream products formed when reactive compounds are processed through glutathione-dependent pathways and excreted. If urinary excretion rises after an intervention, that can indicate increased metabolism and elimination of the measured compound.

That is a real biological endpoint. But it remains a surrogate biomarker. It does not automatically tell us whether a person will develop less cardiovascular disease, COPD or cancer years later.

The strongest human sulforaphane detoxification trials

The 2014 Qidong trial: the landmark human pollution study

The best-known trial randomized 291 adults living in a region with substantial airborne-pollutant exposure to a daily broccoli sprout beverage or placebo for 12 weeks. The active beverage supplied both glucoraphanin and sulforaphane.^[1]

Compared with placebo, urinary excretion of a benzene-derived mercapturic acid increased by 61%, while an acrolein-derived metabolite increased by 23%. The crotonaldehyde biomarker did not significantly change.

Why that nuance matters: even within the same trial, the response was chemical-specific. “Sulforaphane detoxifies pollutants” is less accurate than “a defined broccoli sprout intervention increased excretion of selected pollutant metabolites.”

Does the effect depend on dose?

Apparently, at least for the benzene endpoint tested. A later randomized Qidong study assigned 170 adults to placebo or one of three broccoli sprout beverage concentrations. Only the highest tested concentration significantly increased urinary S-phenylmercapturic acid, a benzene metabolism biomarker.^[2]

This is important because it argues against treating “some sulforaphane” as a binary exposure. Delivered dose still matters. Our sulforaphane bioavailability guide explains why precursor dose, myrosinase and formulation can materially change the dose the body actually receives.

What about cigarette smoke?

A 2022 randomized crossover trial studied 49 current smokers using Avmacol, a glucoraphanin + active-myrosinase broccoli seed/sprout extract. Participants received two glucoraphanin doses in separate treatment periods.^[3]

The higher dose significantly increased urinary detoxification biomarkers for benzene, acrolein and crotonaldehyde. That is stronger than extrapolating from generic sulforaphane biology because the finished commercial formulation itself was used in the trial.

It still does not mean Avmacol or another sulforaphane product makes smoking safe, repairs established lung damage or prevents smoking-related cancer. The primary intervention for tobacco exposure remains stopping the exposure.

How could sulforaphane change pollutant metabolism?

Sulforaphane is an electrophilic compound that can modify KEAP1-related signaling and influence NRF2-dependent stress-response genes. Downstream systems include glutathione synthesis and Phase II enzymes such as glutathione S-transferases, which participate in conjugating and eliminating some reactive chemicals.

Human airway research shows that broccoli-sprout-derived sulforaphane can increase expression of several Phase II response genes in healthy airway cells.^[4] But a COPD randomized trial later found no significant increase in its prespecified NRF2 targets despite measurable absorption.^[5]

That is why we treat the mechanism as supportive context—not proof that every exposure, tissue or disease state responds the same way. See our Sulforaphane & NRF2 guide for the positive-versus-null human evidence.

What sulforaphane detoxification evidence does not show

• It does not show a whole-body cleanse. The trials measured selected chemicals and metabolites.
• It does not show liver “cleansing.” The strongest human evidence is based on urinary xenobiotic biomarkers, not reversal of liver disease.
• It does not prove cancer prevention. Increased excretion of a carcinogen metabolite is biologically relevant but is not the same as lower cancer incidence.
• It does not neutralize smoking. Biomarker modulation cannot offset the established harms of ongoing tobacco exposure.
• It does not replace pollution control. Reducing exposure remains more important than trying to modify metabolism after exposure.

Is this evidence relevant to supplements?

Yes, but formulation matching matters. The Qidong studies used defined broccoli sprout beverages, while the smoking crossover directly tested Avmacol. A product that merely lists “broccoli extract” cannot automatically inherit those results.

For glucoraphanin-based supplements, active myrosinase is one of the strongest human-supported determinants of conversion. See our myrosinase guide and the sulforaphane supplement guide before comparing labels.

Bottom line

The most defensible human “detox” claim for sulforaphane is specific: defined broccoli-derived interventions can increase urinary elimination of selected pollutant and tobacco-smoke metabolites, and the effect can be dose- and formulation-dependent.

That is scientifically interesting. It is not evidence for a generic cleanse, liver repair, protection that makes pollution harmless or prevention of smoking-related cancer.